Related Experiment Videos
Novel approaches to intraperitoneal drug delivery
S B Howell1, S Kirmani, R Goel
1Department of Medicine, University of California, San Diego La Jolla 92093.
Acta Medica Austriaca
|January 1, 1989
Summary
Continuous intraperitoneal infusion of cytarabine (ara-C) showed no plasma detection over 3 weeks. Dipyridamole did not synergize with methotrexate but did with etoposide in ovarian cancer cells.
Area of Science:
- Oncology
- Pharmacology
- Cancer Cell Biology
Background:
- Intraperitoneal chemotherapy offers targeted drug delivery for ovarian cancer.
- Understanding drug interactions is crucial for optimizing treatment efficacy.
- Cytarabine (ara-C) and methotrexate are used in cancer therapy, while dipyridamole can modulate drug activity.
Purpose of the Study:
- To evaluate the pharmacokinetics of prolonged intraperitoneal cytarabine infusion.
- To investigate potential synergistic interactions between dipyridamole and methotrexate.
- To assess the combined effect of dipyridamole and etoposide on a human ovarian carcinoma cell line.
Main Methods:
- Administered prolonged continuous intraperitoneal infusion of cytarabine over 28 treatment courses.
- Monitored plasma levels of cytarabine during treatment.
- Assessed drug interactions through in vitro studies using a human ovarian carcinoma cell line.
Main Results:
- Cytarabine was undetectable in patient plasma during 3-week intraperitoneal infusions.
- No synergistic interaction was observed between intraperitoneal methotrexate and dipyridamole.
- A clear synergistic effect was observed between dipyridamole and etoposide in the ovarian cancer cell line.
Conclusions:
- Prolonged intraperitoneal cytarabine infusion may limit systemic exposure.
- Dipyridamole does not enhance methotrexate efficacy in this context.
- Dipyridamole demonstrates potential synergistic activity with etoposide in ovarian cancer treatment.